Progenics, Ono Pharmaceutical To Initiate RELISTOR Clinical Trials
Published: 08-Jun-2009
RELISTOR, a subcutaneous injection for opioid induced constipation
Progenics and Ono Pharmaceutical announced that they have started clinical testing of RELISTOR (methylnaltrexone bromide) subcutaneous injection in Japan. Its the first in class medicine approved in the US, Canada, EU, Australia and Latin American countries for the treatment of opioid induced constipation.
Ono has exclusive rights to subcutaneous RELISTOR in Japan, where it is pursuing plans to develop and commercialize the drug, designated ONO-3849, for the treatment of opioid induced constipation. RELISTOR is being developed and commercialized in the rest of the world by Progenics and Wyeth Pharmaceuticals.
ONO-3849 is being developed in Japan according to the regulatory agency guidelines of Japan's Ministry of Health, Labor and Welfare, and will be evaluated in Japanese patients with opioid-induced constipation.
Delicious
Digg
Reddit
Stumble
Facebook
LinkedInNetwork Sites
Mail sent successfully
Suppliers To This Sector
Browse A-Z
Treff
Custom Moulded Plastic Parts ...
IRW
Full-Service Nordic Clinical Research Organisation (CRO) ...
Bioceros
Pre-Clinical Development of Monoclonal Antibodies and Generation of GMP-Ready Proteins ...
AR2i
Liquid Handling, Laboratory Material and Technology, Aparatus, Automation and Glassware ...
Bachem
Process Development and Manufacturing of Peptides and Complex Organic Molecules as APIs ...
Lonza Custom Manufacturing
Bioresearch Products, Development Services and Manufacturing for Functional and Active Ingredients ...
White Papers
Browse A-Z
Water Treatment
From the control room to the downstream processing area and with an eye on utilities servi ...
A Vaccinne Bioassay Case Study – A Successful Strategic Outsourcing Model
Increasingly, pharma and biotech firms are searching for new drivers of revenue and profit ...
USB HotStart-IT for Real Time PCR
USB® Products from Affymetrix have a long-standing reputation in the life science marketpl ...
Enabling Drug Delivery Deal Making
Transdermal drug delivery: Time for a closer look. To find out more download this free whi ...
Automating Training Control Processes to Comply with FDA Requirements
Well-managed training programs minimize the risk of non-compliance and improve product qua ...
TNO Pharma Services: From Discovery to the Clinic
Our kinetics & metabolism experts can help you select and further develop your candidate d ...
